Современные подходы к терапии тяжелых форм псориаза

А.П. Музыченко, Т.А. Сикорская, М.В. Качук УО «Белорусский государственный медицинский университет»

2017 №3 | Оригинальные научные публикации

Аннотация

Список литературы

Псориаз html5-dom-document-internal-entity2-61485-end хроническое, воспалительное, мультифакторное заболевание с преимущественным поражением кожи, которым страдает приблизительно 2-3% населения. Лечение должно быть адаптировано для каждого конкретного пациента. Мы детально обсудим эффективность и безопасность использования синтетического ретиноида ацитретина при псориазе. В настоящее время его применение одобрено FDA для лечения тяжелых форм псориаза у взрослых, а также он может применяться в качестве терапии второй линии псориаза, резистентного к использованию топической терапии.

Ключевые слова:

псориаз, ароматические ретиноиды, ацитретин, PASI

Modern therapeutic considerations for severe psoriasis

Psoriasis is a common, chronic, inhtml5-dom-document-internal-entity2-64258-endammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2-3% of the population.Treatment should be tailored to meet individual patients’ needs. We will discuss in detail the efficacy and safety for the use a synthetic retinoid acitretin in psoriasis. It is currently approved by the US Food and Drug Administration for the treatment of severe psoriasis in adults and has been established as a second-line therapy for the treatment of psoriasis resistant to the use of topical therapy.

Keywords

psoriasis, aromatic retinoid, acitretin, PASI

1. Berger, K. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany / K. Berger [et all.] // J. Germ. Soc. Dermatol.- 2005.  P. 511–518.
2. Colombo, G.L. Moderate and severe plaque psoriasis: cost-of-illness study in Italy / G.L. Colombo [et al.] // Clin. Risk Manag. - 2008.- P. 559-568.
3. Navarini, A.A. Estimation of cost-of-illness in patients with psoriasis in Switzerland / A.A. Navarini [et all.] // Swiss Medical Weekly.  2010.  P. 85-91.
4. Murray, H.E. A 12-month treatment of severe psoriasis with acitretin – results of a Canadian open multicenter study / H.E. Murray [et all.] // J. Am. Acad. Dermatol.  1991.  Vol. 24.  P. 598-602.
5. Zachariae, H. Methotrexate and etretinate as concurrent therapies in the treatment of psoriasis / H. Zachariae // Arch. Dermatol.  1984.  P. 120-155.
6. Katz, H.I. Acitretin in psoriasis: an overview of adverse effects / Katz H.I., Waalen J., Leach EE. // J. Am. Acad. Dermatol.  1999.  Vol. 41.  P. 7–12.
7. Mancano, M.A. Drug interactions with oral contraceptives / M.A. Mancano // Pharm. Times.  2000.  Vol. 66.  P.26.
8. Ormerod, A.D. British Association of Dermatologists guidelines on the efﬁcacy and use of acitretin in dermatology / A.D. Ormerod, E. Campalani, M.J.D. Goodﬁeld // British Journal of Dermatology.  2010.  P. 952-963.
9. Menter, A. Guidelines of care for the management of psoriasis and psoriatic arthritis / A. Menter [et al.] // J.A.D.  Vol. 61.  № 3.  P. 451-485.
10. Gupta, М.А. Age and gender differences in the impact of psoriasis on quality of life / Gupta, М.А., Gupta АК. // Int. J. Dermatol.  1995.  Vol. 34.  P. 700-703.
11. Примак, А.В. Функциональный подход к этиологии, патогенезу и лечению псориаза / А.В. Примак// Эстетическая медицина. - 2007.-Т. VI, № 4.- С. 467-477.
12. Prinz, J.C. Theroleofstreptococciinpsoriasis / J.C. Prinz // Hautarzt.  2009. Vol. 60(2). P. 109-115.
13. Kurd, S. The risk of depression, anxiety and suicidality in patient with psoriasis: a population-based cohort study / S. Kurd [et al.] // Archives of Dermatology.  2010.  Vol. 146(8).  P. 891-895.
14. Neimann, A.L. Prevalence of cardiovascular risk factors in patients with psoriasis / A.L. Neimann [et al.] // Journal of the American Academy of Dermatology.  2006.  55(5).  P. 829-835.
15. Farber, E.M. Third international symposium on psoriasis // E.M. Farber, M.L. Nall, W. Watson // Arch. Dermatol.-2007.-Vol. 109. - P. 207-211.
16. Larsen, F.G. Acitretin is converted toetretinate only during concomitant alcohol intake / F.J. Larsen [et all.] // Br. J. Dermatol.  2000.  Vol. 143.  P. 1164–1169.
17. Imcke, E. Cultivation of humandermal microvascular endothelial cells in vitro: immunocytochemical and ultrastructural characterization and effect of treatment with three synthetic retinoids / E. Imcke [et all.] // Arch. Dermatol. Res.  1991. Vol. 283.  P. 149-157.
18. Goldfarb, M.T. Acitretin improves psoriasis in a dose-dependent fashion / M.T. Goldfarb [et all.] // J. Am. Acad. Dermatol.  1988.  Vol. 18.  P. 655-662.
19. Lassus, A. Treatment of severe psoriasis with etretin / A. Lassus [et all.] // Br. J. Dermatol.  1987.  Vol. 117.  P. 333-341.
20. Gupta, A.K., Side-effect proﬁle of acitretin therapy in psoriasis / A.K. Gupta [et all.] // J. Am. Acad. Dermatol.  1989.  Vol. 20.  P. 1088-1093.
21. Gollnick, H. Acitretin versus etretinate in psoriasis – clinical and pharmacokinetic results of a German multicenter study / H. Gollnick [et all.] // J. Am. Acad. Dermatol.  1988.  Vol. 19.  P. 458-468.
22. Murray, H.E. A 12-month treatment of severe psoriasis with acitretin – results of a Canadian open multicenter study / H.E. Murray [et all.] // J. Am. Acad. Dermatol.  1991.  Vol. 24.  P. 598-602.
23. Kragballe, K. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis – results of a Nordic multicenter study / K. Kragballe [et all.] // Act. Derm.Venereol. (Stockh).  1989.  Vol. 69.  P. 35-40.
24. Pearce, D.J. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis / D.J. Pearce [et all.] // Arch. Dermatol. 2006.  142.  P. 1000-1004.
25. Ling, M.R. Acitretin: optimal dosing strategies / M.R. Ling // J. Am. Acad. Dermatol.  1999.  Vol. 41.  P. 13–17.
26. Meffert, H. Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate / H. Meffert, N. Sonnichsen // Acta Derm.Venereol. (Stockh).  1989.  Vol. 146.  P.176-177.
27. Geiger, J.M. Efﬁcacy of acitretin in severe psoriasis / J.M. Geiger // Skin. Ther. Lett.  2003.  Vol. 8.  P. 1-3.
28. Tosti, A. Evaluation of the efﬁcacy of acitretin therapy for nail psoriasis / A. v [et all.] // Arch. Dermatol. 2009.  Vol. 145.  P. 269-271.
29. Buccheri, L., Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection / L. Buccheri [et all.] // Arch. Dermatol.  1997.  Vol. 133.  P. 711-5.